Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism

Bone

Volumn 46, Issue 2, 2010, Pages 524-533

  Schulze, Jochen ^a   Albers, Joachim ^a   Baranowsky, Anke ^a   Keller, Johannes ^a   Spiro, Alexander ^a   Streichert, Thomas ^a   Zustin, Jozef ^a   Amling, Michael ^a   Schinke, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemokines; Osteoblast; PC 3; Prostate cancer; Rankl

Indexed keywords

CYTOKINE; DENTIN MATRIX PROTEIN 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PICEATANNOL; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE 3; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 11; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ARTICLE; BONE BIOPSY; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINES; CULTURE MEDIA, CONDITIONED; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; OSTEOBLASTS; OSTEOGENESIS; OSTEOLYSIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; WNT PROTEINS;

EID: 74249112769     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.09.024     Document Type: Article

References (58)

1. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 13 (2007) 791-801
2. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 (2006) 2010-2018
3. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. 2 (2002) 584-593
4. Logothetis C.J., and Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5 (2005) 21-28
5. Roudier M.P., Corey E., True L.D., Hiagno C.S., Ott S.M., and Vessell R.L. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat. Res. 118 (2004) 311-339
6. Navone N.M., Olive M., Ozen M., Davis R., Troncoso P., Tu S.M., et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3 (1997) 2493-2500
7. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., and Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17 (1979) 16-23
8. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
9. Glass D.A.I.I., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8 (2005) 751-764
10. Baron R., and Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148 (2007) 2635-2643
11. Hall C.L., Bafico A.N., Dai J.I., Aaronson S.T., and Keller E.T. Prostate cancer cells promote osteoblastic bone metastases through wnts. Cancer Res. 65 (2005) 7554-7560
12. Li Z.G., Yang J., Vazquez E.S., Rose D., Vakar-Lopez F., Mathew P., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27 (2008) 596-603
13. Chen G., Shukeir N., Potti A., Sircar K., Aprikian A., Goltzman D., et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 (2004) 1345-1356
14. Autzen P., Robson C.N., Bjartell A., Malcolm A.J., Johnson M.I., Neal D.E., et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer 78 (1998) 1219-1223
15. Harris S.E., Harris M.A., Mahy P., Wozney J., Feng J.Q., and Mundy G.R. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24 (1994) 204-211
16. Li Z.G., Mathew P., Yang J., Starbuck M.W., Zurita A.J., Liu J., et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118 (2008) 2697-2710
17. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1 (1995) 944-949
18. Schmidt K., Schinke T., Haberland M., Priemel M., Schilling A.F., Mueldner C., et al. The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J. Cell Biol. 168 (2005) 899-910
19. Lin S.K., Kok S.H., Yeh F.T., Kuo M.Y., Lin C.C., Wang C.C., et al. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Arthritis Rheum. 50 (2004) 785-793
20. Frank D.A., Mahajan S., and Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5 (1999) 444-447
21. Su L., and David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J. Biol. Chem. 275 (2000) 12661-12666
22. Seitz S., Priemel M., Zustin J., Beil F.T., Semler J., Minne H., et al. Paget's disease of bone: histologic analysis of 754 patients. J. Bone Miner. Res. 24 (2009) 62-69
23. Huebner A.K., Schinke T., Priemel M., Schilling S., Schilling A.F., Emeson R.B., et al. Calcitonin deficiency in mice progressively results in high bone turnover. J. Bone Miner. Res. 21 (2006) 1924-1934
24. Fizazi K., Yang J., Peleg S., Sikes C.R., Kreimann E.L., Daliani D., et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 9 (2003) 2587-2597
25. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 61 (2001) 5652-5659
26. Aubin I., Adams C.P., Opsahl S., Septier D., Bishop C.E., Auge N., et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat. Genet. 37 (2005) 803-805
27. Morvan F., Boulukos K., Clément-Lacroix P., Roman S., Suc-Royer I., Vayssière B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21 (2006) 934-945
28. Roberts S., Narisawa S., Harmey D., Millán J.L., and Farquharson C. Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J. Bone Miner. Res. 22 (2007) 617-627
29. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006) 1310-1315
30. Schinke T., Gebauer M., Schilling A.F., Lamprianou S., Priemel M., Mueldner C., et al. The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 42 (2008) 524-534
31. Dobreva G., Chahrour M., Dautzenberg M., Chirivella L., Kanzler B., Fariñas I., et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell 125 (2006) 971-986
32. Balkwill F. Cancer and the chemokine network. Nat. Rev., Cancer 4 (2004) 540-550
33. Lu Y., Xiao G., Galson D.L., Nishio Y., Mizokami A., Keller E.T., et al. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int. J. Cancer 121 (2007) 724-733
34. Liu X.H., Kirschenbaum A., Yao S., and Levine A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 146 (2005) 1991-1998
35. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
36. Inoue H., Nishimura K., Oka D., Nakai Y., Shiba M., Tokizane T., et al. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett. 223 (2005) 121-128
37. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., and Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol. 22 (2002) 1172-1183
38. Jukkola T., Sinjushina N., and Partanen J. Drapc1 expression during mouse embryonic development. Gene Expr. Patterns 4 (2004) 755-762
39. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J. Clin. 49 (1999) 8-31
40. Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31 (2000) 578-583
41. Keller E.T., Zhang J., Cooper C.R., Smith P.C., McCauley L.K., Pienta K.J., et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 20 (2001) 333-349
42. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
43. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12 (2006) 6213s-6216s
44. Wu T.T., Sikes R.A., Cui Q., Thalmann G.N., Kao C., Murphy C.F., et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 77 (1998) 887-894
45. Corey E., Quinn J.E., Bladou F., Brown L.G., Roudier M.P., Brown J.M., et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52 (2002) 20-33
46. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411 (2001) 321-325
47. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349 (2003) 2483-2494
48. Valentin-Opran A., Charhon S.A., Meunier P.J., Edouard C.M., and Arlot M.E. Quantitative histology of myeloma-induced bone changes. Br. J. Haematol. 52 (1982) 601-610
49. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6 (2000) 521-528
50. Michigami T., Ihara-Watanabe M., Yamazaki M., and Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61 (2001) 1637-1644
51. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell. Biochem. 89 (2003) 462-473
52. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
53. Murakami T., Maki W., Cardones A.R., Fang H., Tun Kyi A., Nestle F.O., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62 (2002) 7328-7334
54. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., et al. CXCL5 promotes prostate cancer progression. Neoplasia 10 (2008) 244-254
55. Kim Y.H., Park C., Lee J.O., Kim G.Y., Lee W.H., Choi Y.H., et al. Induction of apoptosis by piceatannol in human leukemic U937 cells through down-regulation of Bcl-2 and activation of caspases. Oncol. Rep. 19 (2008) 961-967
56. Jin C.Y., Moon D.O., Lee K.J., Kim M.O., Lee J.D., Choi Y.H., et al. Piceatannol attenuates lipopolysaccharide-induced NF-kappaB activation and NF-kappaB-related proinflammatory mediators in BV2 microglia. Pharmacol. Res. 54 (2006) 461-467
57. Larrosa M, Tomás-Barberán FA, Espín JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr.;43:275-84.
58. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., et al. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172 (2008) 1717-1728